Targeted therapies have transformed the treatment landscape for breast cancer, offering patients more precise and effective options while improving long-term outcomes. Among the most significant advances in recent years is Ribociclib, a selective CDK4/6 inhibitor that has become a cornerstone in the treatment of HR-positive, HER2-negative advanced and metastatic breast cancer.
At Suanfarma, we support pharmaceutical partners with high-quality Ribociclib Succinate API, combining technical expertise, regulatory readiness, and reliable manufacturing capabilities to help accelerate oncology development programs worldwide.
What Is Ribociclib and How Does It Work?
Ribociclib is a targeted anticancer therapy designed to inhibit cyclin-dependent kinases 4 and 6 (CDK4/6), proteins that play a critical role in regulating cell division.
By selectively blocking these kinases, Ribociclib prevents phosphorylation of the retinoblastoma (Rb) protein, stopping cancer cells in the G1 phase of the cell cycle and restoring normal cell cycle control. This mechanism has demonstrated significant clinical benefits when Ribociclib is used in combination with endocrine therapy such as aromatase inhibitors or fulvestrant.
The result is a highly effective oral treatment that helps delay disease progression while maintaining patients’ quality of life.
Clinical and Market Relevance
Ribociclib is widely recognized as one of the leading CDK4/6 inhibitors in oncology.
Its importance continues to grow as breast cancer remains one of the most common cancers worldwide, with approximately 1.5 million potential treatment candidates each year. The global market for Ribociclib is projected to expand at a CAGR of more than 7% through 2033, reflecting increasing adoption and continued therapeutic relevance.
Suanfarma Ribociclib Succinate API
Suanfarma offers Ribociclib Succinate (CAS 1374639-75-4) in Polymorphic Form A, with particle size adaptable to customer-specific requirements.
Our product is supported by extensive analytical and process development work to ensure quality, consistency, and regulatory compliance.
Key Product Features
- Purity greater than 98%
- Total impurities around 0.1%
- Stable at room temperature
- Particle size customizable to customer needs
- Development samples and working standards available with Certificate of Analysis
- GMP production capabilities up to 500 kg per year
- OEB 4 manufacturing facilities with advanced engineering controls
- Competitive pricing and scalable production
- Industrial quantities available from Q3 2025
Regulatory Readiness and Technical Support
Suanfarma provides a comprehensive technical and regulatory package designed to facilitate development and registration activities across global markets.
This includes:
- Complete DMF and CTD documentation
- Confirmed Polymorphic Form A
- Extensive impurity characterization
- Compliance with general regulatory requirements
- Strong technical and regulatory support throughout the project lifecycle
In addition, our process has demonstrated excellent control over impurities, consistently meeting stringent EMA benchmark limits for both early and metastatic breast cancer indications.
Reliable Supply for Oncology Development
Oncology APIs demand the highest standards of quality, safety, and manufacturing expertise. Suanfarma combines global commercial reach with trusted production partners and deep experience in complex active pharmaceutical ingredients.
Our approach ensures:
- Robust and reproducible manufacturing
- Consistent batch-to-batch quality
- Scalable supply for clinical and commercial needs
- Dedicated technical and regulatory assistance
Why Choose Suanfarma for Ribociclib API?
Pharmaceutical companies developing oncology products require more than an API supplier; they need a strategic partner capable of supporting every stage of development and commercialization.
With Suanfarma, partners benefit from:
- Strong oncology pipeline and market expertise
- Proven regulatory and technical know-how
- Global commercial network
- Commitment to innovation, quality, and patient access
- Reliable supply backed by rigorous quality standards
Suanfarma APIs. European manufacturing. Global confidence.
Ribociclib represents a major opportunity in the expanding oncology market, and Suanfarma is ready to support your development and supply needs with a high-quality, regulatory-ready API.
Contact our team to learn more about Ribociclib Succinate and our oncology API capabilities.
